BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

Download these expert-selected slides on optimal treatment of patients with B-cell malignancies with BTK inhibitors
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 559 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of complement inhibition in patients with ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue